The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential

Biochemical and Biophysical Research Communications

Volumn 384, Issue 4, 2009, Pages 471-475

  Mori, Hiroyuki ^a,b,c   Inoki, Ken ^a,b   Masutani, Kohsuke ^c   Wakabayashi, Yu ^d   Komai, Kyoko ^d   Nakagawa, Ryusuke ^d   Guan, Kun Liang ^a,b,e   Yoshimura, Akihiko ^d,f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c KYUSHU UNIVERSITY   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Diabetes; mTOR; Nephropathy; Rapamycin; S6kinase

Indexed keywords

GLUCOSE; LEPTIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; RAPAMYCIN; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; GLUCOSE BLOOD LEVEL; HISTOLOGY; HYPERINSULINEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; MALE; MESANGIUM CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; KIDNEY; KIDNEY FAILURE, CHRONIC; MICE; MICE, INBRED STRAINS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RESTRICTION MAPPING; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS;

MUS;

EID: 65649120747     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.04.136     Document Type: Article

References (17)

1. Cooper M.E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352 (1998) 213-219
2. Parving H.H., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., and Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345 (2001) 870-878
3. Fioretto P., Steffes M.W., and Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 43 (1994) 1358-1364
4. Caramori M.L., Kim Y., Huang C., Fish A.J., Rich S.S., Miller M.E., Russell G., and Mauer M. Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes 51 (2002) 506-513
5. Schrijvers B.F., De Vriese A.S., and Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr. Rev. 25 (2004) 971-1010
6. Berthier C.C., Zhang H., Schin M., Henger M.A., Nelson R.G., Yee B., Boucherot A., Neusser M.A., Cohen C.D., Carter-Su C., Argetsinger L.S., Rastaldi M.P., Brosius F.C., and Kretzler M. Enhanced expression of JAK-STAT pathway members in human diabetic nephropathy. Diabetes 58 (2009) 469-477
7. Tsang C.K., Qi H., Liu L.F., and Zheng X.F. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 12 (2007) 112-124
8. Hidalgo M., and Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 (2000) 6680-6686
9. Leibowitz G., Cerasi E., and Ketzinel-Gilad M. The role of mTOR in the adaptation and failure of beta-cells in type 2 diabetes. Diabetes Obes. Metab. 10 (2008) 157-169
10. Sataranatarajan K., Mariappan M.M., Lee M.J., Feliers D., Choudhury G.G., Barnes J.L., and Kasinath B.S. Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am. J. Pathol. 171 (2007) 1733-1742
11. Nakao N., Hiraiwa N., Yoshiki A., Ike F., and Kusakabe M. Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture. Am. J. Pathol. 152 (1998) 1237-1245
12. Torisu T., Sato N., Yoshiga D., Kobayashi T., Yoshioka T., Mori H., Iida M., and Yoshimura A. The dual function of hepatic SOCS3 in insulin resistance in vivo. Genes Cells 12 (2007) 143-154
13. Lee S.M., and Bressler R. Prevention of diabetic nephropathy by diet control in the db/db mouse. Diabetes 30 (1981) 106-111
14. Fingar D.C., Salama S., Tsou C., Harlow E., and Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 16 (2002) 1472-1487
15. Wendel H.G., De Stanchin E., Fridman J.S., Malina A., Ray S., Kogan S., Cordpn-Cardo C., Pelletier J., and Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
16. Shamji A.F., Nghiem P., and Schreiber S.L. Integration of growth factor and nutrient signaling: implications for cancer biology. Mol. Cell 12 (2003) 271-280
17. Hering B.J., and Wijkstrom M. Sirolimus and islet transplants. Transplant. Proc. 35 (2003) 187S-190S